rcs research tirzepatide Dual Agonist (GLP-1/GIP) Tirzepatide Dual Agonist (GLP-1/GIP) |
Description
From study baseline to the end of follow-up, GLP-1RAs treatment resulted in statistically significant decreases in weight (MD=-2.32 kg, 95% CI: -4.21 to -0.43) and BMI (MD=-0.82 kg/m2, 95% CI: -1.47 to -0.17)

Design Population based cohort study using a prevalent new-user design, emulating a trial

(A) Taking sleeve gastrectomy (LSG) and Roux-en-Y gastric bypass (RYGB) as the archetypal examples of metabolic bariatric operations, both procedures lead to a net increase of endogenous GLP-1 with different mechanisms: LSG via rapid gastric emptying and RYGB due to the presence of undigested nutrients in the intestinal lumen in segments rich in L-cells, such as the ileum[45,46]
Understanding the mechanism helps explain why personalized dosing and genetic factors matter for your weight loss success
With a tested purity of 99.9%, this compound is ideal for laboratory studies exploring mechanisms related to metabolic regulation, GLP-1/GIP analogs, or peptide stability

Compounded vs brand-name GLP-1s compared cost, FDA status, safety, and how to choose
